LGM

Logos Global Management Portfolio holdings

AUM $1.5B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
1 Year Est. Return
+197.64%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$1.01B
AUM Growth
+$264M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
71
New
Increased
Reduced
Closed

Top Buys

1
+$25.4M
2
+$22.7M
3
+$20.7M
4
LBRX
LB Pharmaceuticals
LBRX
+$17.9M
5
ARVN icon
Arvinas
ARVN
+$17.3M

Top Sells

1
+$30M
2
+$26.5M
3
+$24.4M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$18.9M
5
KROS icon
Keros Therapeutics
KROS
+$17M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MREO
51
Mereo BioPharma
MREO
$59M
$1.03M 0.1%
+500,000
GUTS icon
52
Fractyl Health
GUTS
$72M
$795K 0.08%
+500,000
NUVB.WS
53
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$13.5K ﹤0.01%
66,666
XNCR icon
54
Xencor
XNCR
$912M
– –
-1,250,000
APLS icon
55
Apellis Pharmaceuticals
APLS
$2.68B
– –
0
KRYS icon
56
Krystal Biotech
KRYS
$8.06B
– –
-100,000
LEGN icon
57
Legend Biotech
LEGN
$3.51B
– –
-250,000
LRMR icon
58
Larimar Therapeutics
LRMR
$441M
– –
0
BCAX
59
Bicara Therapeutics
BCAX
$919M
– –
-400,000
MTSR
60
DELISTED
Metsera Inc
MTSR
– –
-200,000
ALEC icon
61
Alector
ALEC
$265M
– –
0
ANNX icon
62
Annexon
ANNX
$835M
– –
-2,410,000
BHVN icon
63
Biohaven
BHVN
$1.53B
– –
-700,000
CLDX icon
64
Celldex Therapeutics
CLDX
$2B
– –
-600,000
MDGL icon
65
Madrigal Pharmaceuticals
MDGL
$9.81B
– –
-50,000
MLTX icon
66
MoonLake Immunotherapeutics
MLTX
$1.24B
– –
-200,000
NBIX icon
67
Neurocrine Biosciences
NBIX
$13.3B
– –
-150,000
TEVA icon
68
Teva Pharmaceuticals
TEVA
$39.4B
– –
0
UTHR icon
69
United Therapeutics
UTHR
$21.7B
– –
-85,000
XBI icon
70
State Street SPDR S&P Biotech ETF
XBI
$8.34B
– –
0
RAPP
71
Rapport Therapeutics
RAPP
$1.38B
– –
-208,910
1 2
3